177 US companies filed quarterly results with the SEC (8-K Item 2.02). We read 166 and called the likely one-week price move. Calls are graded in the open.
Qualys reported strong Q3 revenue growth of 11% year-over-year and raised its 2026 revenue guidance, driven by increasing adoption of its AI-native Risk Operations Center and a partner-first strategy.
OUR ANALYSIS → VIEW 8-K →This 8-K filing is an update to the investor presentation, which does not contain any quantified surprises or significant new information that would impact the stock price, and the forward-looking statements are uncertain and subject to various risks and uncertainties.
OUR ANALYSIS → VIEW 8-K →USA Rare Earth reported Q3 revenues of $3.0 million and a cash balance of $1.2 billion, with significant operational milestones including the completion of the Serra Verde combination and commencement of commercial-scale MREC production, but the filing lacks specific quantified surprises to gauge the stock's movement.
OUR ANALYSIS → VIEW 8-K →H&R Block reported a 10% increase in revenue for the fiscal 2027 first quarter, with total revenue of $224.3 million, and reaffirmed its fiscal 2027 outlook, but the net loss from continuing operations increased by 13.8% to ($188.1) million
OUR ANALYSIS → VIEW 8-K →Larimar Therapeutics has completed its rolling Biologics License Application submission to the FDA for accelerated approval of nomlabofusp, a potential disease-modifying therapy for Friedreich's ataxia, and has approximately $128.7 million in cash and cash equivalents as of September 30, 2026. The submission is a significant milestone, but the impact on the stock price will depend on the FDA's rev
OUR ANALYSIS → VIEW 8-K →Paradium.AI's Q3 2026 revenue declined 31.2% year-over-year to $20.5 million, with a net loss of $3.8 million, due to lower referral traffic and compressed margins, despite momentum in monetization and technology initiatives.
OUR ANALYSIS → VIEW 8-K →The company's 8-K filing includes its third quarter financial results, which may contain quantified surprises, but the provided text does not disclose specific numbers or comparisons to guidance or previous periods, making it difficult to assess the impact without further information.
OUR ANALYSIS → VIEW 8-K →Praxis Precision Medicines reported its Q3 2026 financial results, with cash and investments of approximately $1.3 billion, and provided updates on its pipeline, including the ongoing FDA reviews of relutrigine and ulixacaltamide, but no quantified surprises were disclosed.
OUR ANALYSIS → VIEW 8-K →Ispire Technology Inc. reported a 3.2% sequential revenue increase to $27.5 million and a return to positive Adjusted EBITDA, but the year-over-year revenue decrease and increased operating expenses may temper investor enthusiasm. The company's progress in stabilizing the business and improving operational efficiency is notable, but the stock's reaction will depend on how these results compare to
OUR ANALYSIS → VIEW 8-K →Ur-Energy reports a 67% year-over-year increase in sales and a 26% increase in captured pounds, with low cash costs per produced pound, indicating a strong operational performance. However, the filing does not contain any major quantified surprises beyond the expected quarterly results.
OUR ANALYSIS → VIEW 8-K →Rani Therapeutics reported a net loss for the third quarter and had cash, cash equivalents, and marketable securities of $45.3 million, expecting to fund operations through the end of 2027. The company's acceptance into the FDA's Emerging Technology Program and continued enrollment in the RT-114 Phase 1a expansion cohort are positive developments, but the financial results do not contain significa
OUR ANALYSIS → VIEW 8-K →EquipmentShare.com Inc reported strong Q3 results with 55% year-over-year revenue growth and 52% growth in Rental Segment Adjusted EBITDA, driven by accelerated organic growth and margin expansion. The company's guidance and outlook suggest confidence in outperforming full-year 2026 expectations.
OUR ANALYSIS → VIEW 8-K →Tidewater Inc. reported a 5.3% increase in revenue and a 3.7% increase in average day rate, with net income of $17.5 million and Adjusted EBITDA of $140.1 million, also updating 2026 revenue guidance and initiating 2027 guidance, but the filing lacks a significant quantified surprise to move the stock beyond routine expectations
OUR ANALYSIS → VIEW 8-K →The company reported encouraging clinical findings for its pipeline programs, including bamzireotide navoxetan and lapemelanotide zapixetar, and received Fast Track Designation from the FDA for PSV359, but no quantified surprises were disclosed in the filing.
OUR ANALYSIS → VIEW 8-K →Babcock & Wilcox Enterprises, Inc. reported a significant increase in revenue and net income for the third quarter of 2026, with revenue up 109% and net income of $94 million, and also announced a full year 2027 Adjusted EBITDA target range of $125 million to $140 million, indicating strong growth prospects.
OUR ANALYSIS → VIEW 8-K →Rackspace Technology reported a 9% year-over-year decline in revenue, but raised its full-year 2026 revenue outlook by $35 million at the midpoint, and maintained its non-GAAP operating profit and adjusted EBITDA outlook. The company's private cloud revenue increased 4% year-over-year, while public cloud revenue decreased 17% year-over-year.
OUR ANALYSIS → VIEW 8-K →The company reported a GAAP net loss of $8.4 million and Adjusted EBITDA of -$4.9 million, but anticipates positive Adjusted EBITDA in the fourth quarter and full-year 2026, driven by strong biodiesel demand and improved production economics, as well as a new relationship with a large European chemicals customer.
OUR ANALYSIS → VIEW 8-K →Coherus Oncology reported Q3 2026 financial results with LOQTORZI net revenue of $14.0 million, a 25% increase over Q3 2025, and announced a strategic prioritization plan focusing on tagmokitug/toripalimab for esophageal cancer, which may lead to expedited development and potential financial benefits, but also involves a 30% reduction in headcount and deprioritization of other development efforts
OUR ANALYSIS → VIEW 8-K →Harrow, Inc. reported record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year, and reaffirmed full-year 2026 revenue guidance of $350 million to $365 million, but updated full-year 2026 Adjusted EBITDA guidance to more than $40 million, which is lower than the prior guidance of $80 million to $100 million.
OUR ANALYSIS → VIEW 8-K →Occidental Petroleum reported strong Q3 2026 results, exceeding guidance with $1.61 EPS and $1.91 adjusted EPS, and reducing principal debt to $10.0 billion, but the announcement lacks a significant quantified surprise to drive a large price move.
OUR ANALYSIS → VIEW 8-K →American Public Education exceeded guidance for third quarter revenue, net income, EPS, and adjusted EBITDA, and raised full year 2026 guidance across all key metrics, driven by growth in Health+ segment and improved operational efficiency
OUR ANALYSIS → VIEW 8-K →Life360 reported strong Q3 2026 results with 40% year-over-year revenue growth to $174.1 million and record net Paying Circle additions, beating expectations and demonstrating the company's ability to deliver value to shareholders.
OUR ANALYSIS → VIEW 8-K →Clearway Energy, Inc. reported third quarter 2026 financial results, including Net Income of $123 million, Adjusted EBITDA of $435 million, and Cash Available for Distribution (CAFD) of $173 million, while also reaffirming 2026 financial guidance and initiating 2027 financial guidance, indicating a positive outlook for the company's growth and financial performance.
OUR ANALYSIS → VIEW 8-K →Total Net Bookings decreased 18% year-over-year to $1.60 billion, and the company reported a GAAP net loss of $54.0 million, but is reiterating its fiscal year 2027 outlook for Net Bookings of $8.0 to $8.2 billion, citing strong pre-orders for Grand Theft Auto VI. The upcoming launch of Grand Theft Auto VI is expected to drive historic year performance, but current quarterly results show a decline
OUR ANALYSIS → VIEW 8-K →Definium Therapeutics reported positive topline Phase 3 results for DT120 ODT in generalized anxiety disorder and received FDA Breakthrough Therapy Designation for DT120 ODT in major depressive disorder, with approximately $1.05 billion in cash and cash equivalents as of September 30, 2026.
OUR ANALYSIS → VIEW 8-K →Crescent Capital BDC, Inc. reported net investment income of $0.37 per share and net income of $0.27 per share for the quarter ended September 30, 2026, and announced a $50 million share repurchase program, which may be viewed positively by investors.
OUR ANALYSIS → VIEW 8-K →ZipRecruiter's Q3 revenue and Adjusted EBITDA came in above the high end of their guidance range, with revenue of $124.4 million and Adjusted EBITDA of $20.8 million, and they are raising their full-year 2026 outlook, indicating stronger than expected growth and profitability.
OUR ANALYSIS → VIEW 8-K →Lucid Group reduced cash consumption by 30% sequentially and increased liquidity by $1.75 billion through expanded support from the PIF, but the filing lacks specific quantified surprises on earnings or guidance beats.
OUR ANALYSIS → VIEW 8-K →The company reported a significant increase in net income and adjusted EBITDA, but the filing lacks specific quantified surprises that would significantly impact the stock price. The provided information is largely routine and already priced in.
OUR ANALYSIS → VIEW 8-K →KALA BIO reports a 90% year-over-year reduction in quarterly net loss to $0.8 million and has $7.0 million in cash with no debt, but this is preliminary and unaudited, subject to completion of financial close procedures and review by its independent auditor.
OUR ANALYSIS → VIEW 8-K →Fervo Energy reported Q3 net income of $11.7 million, but a net loss attributable to common stockholders of $20.8 million, and announced a major power purchase agreement with Google, which is a significant positive development, however, the company also reported a large operating loss and high capital expenditures, which may offset some of the positive news
OUR ANALYSIS → VIEW 8-K →The company reported a strong cash position of $359.7 million, which provides a runway into the first quarter of 2029, and is on track to complete PPQ runs by year-end 2026 to support the planned Biologics License Application (BLA) submission for NGN-401, but there are no quantified surprises in the filing.
OUR ANALYSIS → VIEW 8-K →The company reported a net loss of $21.2 million for the quarter ended September 30, 2026, and cash, cash equivalents, and short-term investments of $169.7 million, anticipated to fund operations into 2H 2028. No significant quantified surprises were disclosed in the filing.
OUR ANALYSIS → VIEW 8-K →Tonix Pharmaceuticals reported a 37% increase in TONMYA net sales to $15 million and has approximately $163 million in cash and cash equivalents, but also announced that Dr. Reddy's Laboratories has filed an ANDA for a generic version of TONMYA, which could potentially impact future sales.
OUR ANALYSIS → VIEW 8-K →Ocular Therapeutix reported a cash balance of $530.6 million as of September 30, 2026, and is on track to submit its NDA for AXPAXLI in wet AMD in the fourth quarter, with a strong commercial readiness plan in place.
OUR ANALYSIS → VIEW 8-K →TG Therapeutics raises full-year 2026 total global revenue guidance to approximately $1 billion and full-year 2026 BRIUMVI U.S. net product revenue guidance to approximately $915-920 million, driven by solid third-quarter performance and a strong anticipated fourth quarter, with the company highlighting continued momentum in its IV business and potential to expand the BRIUMVI franchise through new
OUR ANALYSIS → VIEW 8-K →Ionis Pharmaceuticals reported Q3 financial results with total revenue increasing 55% year-over-year, driven by commercial and R&D revenue growth, but lowered 2026 product sales guidance for TRYNGOLZA due to a more gradual than expected launch ramp, while reaffirming total revenue and operating loss guidance
OUR ANALYSIS → VIEW 8-K →NESR reported a 70.9% year-over-year increase in revenue and a 93.5% year-over-year increase in net income, with diluted EPS rising 83.3% year-over-year to $0.33, but the stock's reaction will depend on whether these results exceeded market expectations
OUR ANALYSIS → VIEW 8-K →Microvast's Q3 2026 results show a significant decline in sales, gross margin, and operating performance, with a net loss of $76.8 million and non-GAAP adjusted net loss of $76.0 million, prompting concerns about liquidity and debt obligations. The company's focus on reducing costs and preserving liquidity may not be enough to offset the decline in demand and pricing pressures in the industry.
OUR ANALYSIS → VIEW 8-K →Nine Energy Service reported third quarter 2026 revenues of $142.0 million, net loss of $(5.1) million, and adjusted EBITDA of $8.3 million, with cementing revenue increasing 11% quarter over quarter, but the results are largely in line with expectations and do not contain significant quantified surprises
OUR ANALYSIS → VIEW 8-K →The company announced a $1.0 billion non-dilutive funding for manufacturing and launch of midband satellites and expects to achieve intermittent nationwide service activation in key markets by year-end 2026, with a production rate of six ASIC satellites per month in December.
OUR ANALYSIS → VIEW 8-K →Mesa Labs reported a 2.6% increase in revenues and a 77.6% increase in operating income, with adjusted EBITDA growing 21.1% to $17,317, and issued full-year fiscal 2027 guidance for the first time, with revenues expected to be between $250,000 and $255,000 and adjusted EBITDA between $66,000 and $68,000.
OUR ANALYSIS → VIEW 8-K →FiscalNote's Q3 2026 results show a rise in adjusted EBITDA to $3.6 million, with revenue of $18.7 million, and the company reaffirms its FY26 guidance, but the stock's reaction will depend on how these results compare to market expectations, which are not explicitly stated in the filing.
OUR ANALYSIS → VIEW 8-K →The company has reported its third quarter 2026 financial results, which can be found on their website, but no specific quantified surprises are mentioned in the filing.
OUR ANALYSIS → VIEW 8-K →P3 Health Partners Inc. reported strong Q3 2026 results, with adjusted EBITDA of $21 million and raised full-year 2026 adjusted EBITDA guidance midpoint to $100 million, driven by improved network economics and rate progression.
OUR ANALYSIS → VIEW 8-K →Lincoln Educational Services reported strong Q3 results with 14.2% growth in student starts, 12.6% increase in revenue, and 30.8% growth in adjusted EBITDA, also increasing full-year 2026 revenue guidance. The company's share repurchase program and recent business developments, such as new campus leases, are positives.
OUR ANALYSIS → VIEW 8-K →BitGo's Q3 net income of $44.1 million was driven by the appreciation of its digital asset treasury, and the company repurchased $24.7 million of common stock during the quarter, but total revenue declined 50.9% year-over-year to $2,851.9 million
OUR ANALYSIS → VIEW 8-K →Groupon's Q3 results show a 2% increase in global revenue and a 6% increase in billings, with a smaller loss from continuing operations and positive adjusted EBITDA, but the outlook for Q4 and full-year 2026 is relatively flat, with billings and revenue guidance indicating minimal growth
OUR ANALYSIS → VIEW 8-K →The company announced a merger agreement with HealthSpan Partners at $25.00 per share, representing an enterprise value of up to $6.0 billion, and reported third quarter revenue of $815.3 million, a decrease of 0.8% year-over-year, with same-facility revenues increasing 6.0% and Adjusted EBITDA of $132.7 million.
OUR ANALYSIS → VIEW 8-K →Hims & Hers Health, Inc. reported a 49% year-over-year revenue increase to $890 million, with subscribers growing 13% to 2.8 million, and tightened full-year revenue guidance to $3.13-3.15 billion, but reduced Adjusted EBITDA guidance to $257-277 million. The company's strong balance sheet and cash flow generation provide flexibility for long-term investments.
OUR ANALYSIS → VIEW 8-K →Attovia Therapeutics reported positive topline results from its Phase 1b study of ATTO-1310, showing rapid and sustained itch relief in patients with chronic pruritus and high-itch atopic dermatitis, with plans to initiate two Phase 2 trials in the first half of 2027. The results demonstrate the potential for quarterly maintenance dosing of ATTO-1310 and support its further development.
OUR ANALYSIS → VIEW 8-K →Ethan Allen Interiors Inc. reported lower sales and pressured margins due to tariffs, soft housing market, and global unrest, but showed sequential improvement in Retail written orders and has no outstanding debt.
OUR ANALYSIS → VIEW 8-K →QUBT reported Q3 revenue of $9.5 million, exceeding the $9.2 million generated in the entire first half of 2026, with a significant increase in gross margin and a net loss of $15.1 million, but the market may view the revenue growth as a positive surprise given the company's expanding commercial relationships and integration of acquired businesses.
OUR ANALYSIS → VIEW 8-K →PubMatic's Q3 revenue and adjusted EBITDA exceeded guidance, with a 17% revenue increase and 133% adjusted EBITDA growth, and the company's Board of Directors authorized a $150M expansion of its share repurchase program, increasing the total available for repurchase to $198M
OUR ANALYSIS → VIEW 8-K →The company reported a significant increase in revenue and net income for the first fiscal quarter, and announced a definitive merger agreement to be acquired by Madison Dearborn Partners for $2.00 per share, a 100% premium over the closing share price on September 24, 2026. This confirmed takeover at a premium is a quantified surprise that should positively impact the stock price.
OUR ANALYSIS → VIEW 8-K →Telos Corporation reported strong Q3 2026 financial results, with revenue of $55.2 million, exceeding guidance, and raised full year guidance due to new business wins and margin outperformance. The company's GAAP Net Income was $4.4 million and Adjusted EBITDA was $10.6 million, exceeding guidance.
OUR ANALYSIS → VIEW 8-K →The company reported a 6.5% increase in revenue to $1.95 million and a 17.7% narrowing of operating loss year over year, but the filing lacks a quantified surprise to predict a significant price move, and the proposed transaction with Opifex Media Inc. may be a potential catalyst but details are not sufficient to determine its impact.
OUR ANALYSIS → VIEW 8-K →Heron Therapeutics announced a definitive agreement to sell substantially all of its assets to CorMedix Therapeutics, a move that implies significant corporate restructuring and potential dilution or value transfer for existing shareholders. The company also reported Q3 2026 financial results with total net revenue of $35.3 million, a 7.8% decrease from Q3 2025.
OUR ANALYSIS → VIEW 8-K →The company remains on track for its planned BLA submission for TA-ERT in December 2026 and has taken steps to strengthen its balance sheet, but there are no quantified surprises in the filing, and the update is largely routine and already-priced-in news.
OUR ANALYSIS → VIEW 8-K →CECO Environmental Corp reports strong third quarter results with orders, backlog, and adjusted EBITDA up over 200 percent, and updates its full-year 2026 outlook, increasing forecasts for orders and free cash flow. The company's leverage has also decreased to 2.0X, a reduction of 0.7X from the closing date of the Thermon acquisition.
OUR ANALYSIS → VIEW 8-K →The company reported progress in its clinical pipeline, including FDA clearance for a global Phase 2 study of epetraborole in polycythemia vera and enrollment ongoing in a Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease, but no quantified surprises were disclosed.
OUR ANALYSIS → VIEW 8-K →Roivant Sciences reported strong early demand for its newly launched product LISRAYA, with $31 million in net product revenue in its first 5 weeks, and announced positive trial data for several pipeline assets, including IMVT-1402 and mosliciguat.
OUR ANALYSIS → VIEW 8-K →Tango Therapeutics reported promising Phase 1/2 data for vopimetostat plus daraxonrasib in pancreatic cancer, with an 82% objective response rate and 88% 9-month progression-free survival rate, and plans to initiate a registrational Phase 3 study in 1H 2027. The company also has a strong cash position of $977.5 million as of September 30, 2026.
OUR ANALYSIS → VIEW 8-K →The company reported a 5% increase in net sales to $146.0 million and tightened its full-year 2026 net sales forecast to a range of $578.0 million to $585.0 million, with adjusted earnings per diluted share forecast to a range of $0.60 to $0.66, representing 43% growth at the high end.
OUR ANALYSIS → VIEW 8-K →The company reported a net loss of $11 million and a 29% year-over-year decrease in net sales, but gross profit margin improved by 330 basis points, however the sale of its International business is still pending and the company's debt has increased.
OUR ANALYSIS → VIEW 8-K →CEVA reported an 18% sequential royalty revenue growth, record AI licensing revenues, and a multi-year smartphone modem ramp ahead, but GAAP net loss was $2.3 million and GAAP diluted loss per share was $0.08.
OUR ANALYSIS → VIEW 8-K →The company reported its financial results for the quarter ended September 30, 2026, and updated its corporate presentation, but there are no quantified surprises in the filing, and the forward-looking statements are cautionary and subject to risks and uncertainties.
OUR ANALYSIS → VIEW 8-K →Village Farms International reports record cannabis revenues of $55 million and net income of $10 million, driven by strong international sales growth and a competitive advantage with its EU-GMP certified cannabis facility, but notes softer spot trim market conditions in Canada that impacted margins.
OUR ANALYSIS → VIEW 8-K →Virtus Investment Partners reported Q3 2026 earnings per share of $3.26, a 30% decrease from the same period last year, and net flows of ($6.1) billion, with assets under management decreasing to $141.4 billion. The company's revenue and operating income also declined, with revenue down 9% to $197.6 million and operating income down 27% to $34.3 million.
OUR ANALYSIS → VIEW 8-K →Constellation Energy Corp reported Q3 GAAP net income of $5.19 per share and adjusted operating earnings of $5.06 per share, raising and narrowing its full-year adjusted operating earnings guidance to $12.50 - $12.80 per share. The company also announced several new agreements and investments, including the acquisition of the Rhode Island State Energy Center and a long-term collaboration with Goog
OUR ANALYSIS → VIEW 8-K →Solidion Technology reports a strong cash balance, reduced liabilities, and positive EPS, with a healthy cash position of $26.2 million and total liabilities declining by approximately 40% compared to year-end 2025.
OUR ANALYSIS → VIEW 8-K →Consolidated Water Co. Ltd. reported an 11.9% decrease in total revenue and a 57% decrease in net income from continuing operations, but received significant purchase orders and advanced the Hawaii seawater desalination project, which may not be enough to offset the decline in revenue and net income.
OUR ANALYSIS → VIEW 8-K →The company reported a decrease in revenue and Adjusted EBITDA, and a net loss of $5.9 million, due to client payment difficulties and increased marketing spend, with cash and cash equivalents totaling $51.0 million as of September 30, 2026.
OUR ANALYSIS → VIEW 8-K →The company is announcing its Q3 2026 financial results and hosting a conference call, but there is no quantified surprise or significant news in the filing that would impact the stock price beyond 1.5% in a week.
OUR ANALYSIS → VIEW 8-K →Hallador Energy reports Q3 results and provides an update on the Turtle Creek gas project, with contracted forward sales increasing 26% to $3.0 billion and a target of $1.6 billion of value from Turtle Creek within 24 months, but the announcement lacks specific quantified surprises to drive a significant stock move
OUR ANALYSIS → VIEW 8-K →Douglas Elliman Inc. reported a net income of $7.4 million and an operating income of $6.3 million for the third quarter of 2026, with a $10 million share repurchase program announced, but the company's revenue and adjusted EBITDA were lower compared to the same period in 2025. The share repurchase program may be a positive signal, but the overall financial performance is mixed.
OUR ANALYSIS → VIEW 8-K →Exodus Movement, Inc. reported a net loss of $8.3 million for Q3 2026, a significant decline from the net income of $17.0 million in the same period last year, and Adjusted EBITDA was a loss of $3.9 million, down from a positive $5.9 million in Q3 2025. The company is on track to reduce combined annual costs by approximately $30 million going into 2027 due to cost savings initiatives and synergies
OUR ANALYSIS → VIEW 8-K →Summit Midstream Corp raised its 2026 Adjusted EBITDA guidance range to $250-260 million and reported strong Q3 results, with Adjusted EBITDA increasing 16% to $70.7 million, driven by growing Rockies volumes and strong producer activity. The company also announced a final investment decision on the Double E Mainline Compression Expansion, positioning it to serve growing Permian Basin customer dem
OUR ANALYSIS → VIEW 8-K →GMR Solutions Inc. reported a strong third quarter with revenue increasing 5.9% to $1,595.6 million and net income increasing 81.7% to $135.6 million, driven by growth in core emergent services and disciplined cost management. The company also reduced leverage and strengthened its balance sheet through strategic capital transactions.
OUR ANALYSIS → VIEW 8-K →Novanta Inc. reported strong Q3 2026 results with 23% revenue growth and 38% increase in Adjusted EBITDA, exceeding expectations and driven by momentum in customer bookings and acquisition activities.
OUR ANALYSIS → VIEW 8-K →Bally's Corp reports preliminary Q3 revenue of $807.6 million, up 21.7% year-over-year, driven by strong growth in Bally's Intralot B2C and North America Interactive segments, but the company expects to file an extension for its Quarterly Report on Form 10-Q, which may indicate some delays or issues with its financial reporting process.
OUR ANALYSIS → VIEW 8-K →Galaxy Gaming reported a 9% increase in total revenue and a record recurring revenue, but the stock's movement will likely be neutral as the news is already priced in and there are no significant quantified surprises.
OUR ANALYSIS → VIEW 8-K →Bakkt reported Q3 earnings with GAAP net income of $14.3 million and reiterated its $3 billion full-year 2026 Total Transacting Volume target, while also setting a target of $6 billion for the first half of 2027, driven by accelerating client activations and an expanded commercial team. However, the stock's reaction will depend on whether these targets are perceived as already priced in or a posit
OUR ANALYSIS → VIEW 8-K →Ranger Energy Services reported Q3 revenue of $162.8 million, net income of $2.5 million, and Adjusted EBITDA of $20.1 million, also completing the acquisition of STEP Energy Services' US coil tubing assets and securing contracts for four additional ECHO hybrid electric workover rigs, but the announcement lacks a significant quantified surprise to move the stock beyond 1.5% in a week
OUR ANALYSIS → VIEW 8-K →The company corrected its accounting for deferred income taxes, resulting in a $6.0 million increase in income tax provision and a corresponding decrease in net income for both the three and nine months ended September 30, 2026. This non-cash correction had no impact on revenue, operating income, Adjusted EBITDA, or cash flows.
OUR ANALYSIS → VIEW 8-K →JBS N.V. reported a 36% decline in IFRS Adjusted EBITDA and a 58% decline in IFRS Adjusted operating income, with net sales only up 1% from the prior year, indicating a challenging operating environment across several business units, which may negatively impact the stock price. The increase in leverage to 3.54x also raises concerns about the company's financial health.
OUR ANALYSIS → VIEW 8-K →Viant Technology Inc. reported strong third-quarter financial results, exceeding guidance, with revenue increasing 29% year-over-year and adjusted EBITDA increasing 24% year-over-year. The company also announced an increased share repurchase authorization of $50 million to $150 million.
OUR ANALYSIS → VIEW 8-K →Green Dot Corporation reported solid Q3 2026 results with revenue growth and cost control, but the stock's movement will likely be muted as the results were modestly ahead of expectations and the company is preparing for its acquisition by Smith Ventures and CommerceOne. The 21% year-over-year increase in total operating revenues and 9% increase in adjusted EBITDA are notable, but may not be enoug
OUR ANALYSIS → VIEW 8-K →Trevi Therapeutics reported a cash runway into 2030, funding key clinical milestones, and announced positive developments in its chronic cough treatment programs, including a Phase 3 trial initiation and a positive meeting with the FDA, but no quantified surprises were disclosed.
OUR ANALYSIS → VIEW 8-K →AbCellera's Q3 2026 results show a net loss of $40.8 million, but the company raised $200 million in a common share and pre-funded warrant offering, bringing its available liquidity to approximately $900 million. The positive top-line Phase 2 results for ABCL635 and the addition of new pipeline programs are notable, but the capital raise indicates dilution
OUR ANALYSIS → VIEW 8-K →The company reported its third quarter 2026 financial results, which can be viewed on its website, and will host a conference call to discuss the results, but no quantified surprises are disclosed in the filing.
OUR ANALYSIS → VIEW 8-K →Surrozen's recent financing activities, including a private placement and ATM transaction, have extended its anticipated cash runway into 2029, but the capital raise also means dilution for existing shareholders. The company's expansion of the DUET Phase 2a study is a positive development, but it's not a quantified surprise that would significantly move the stock price.
OUR ANALYSIS → VIEW 8-K →The company reported a net loss of $15.6 million for the quarter, with R&D expenses decreasing to $11.3 million and G&A expenses decreasing to $6.0 million, and they have $126.6 million in cash to fund operations into the first quarter of 2028. No significant surprises were reported in the filing, with the company's olevaprubart program progressing as planned.
OUR ANALYSIS → VIEW 8-K →Atea Pharmaceuticals reported positive topline results from its Phase 3 C-BEYOND trial, demonstrating statistical non-inferiority of BEM/RZR to Epclusa in patients with HCV, and secured non-dilutive funding of up to $200 million from Hercules Capital, which is a significant positive development for the company.
OUR ANALYSIS → VIEW 8-K →Lineage's third-quarter results showed a decrease in total revenue and adjusted EBITDA, with adjusted EBITDA margin decreasing by 150 basis points, and the company has adjusted its full-year guidance accordingly, citing temporary pressures from higher oil prices and tariff uncertainty.
OUR ANALYSIS → VIEW 8-K →FreightCar America's third-quarter results were consistent with preliminary figures, with a 28% year-over-year increase in backlog value and 65% growth in aftermarket revenue, but gross margin and adjusted EBITDA declined significantly due to a challenging period for the business.
OUR ANALYSIS → VIEW 8-K →HF Foods Group Inc. reported a 4.1% increase in net revenue to $319.6 million, but a 385.9% increase in GAAP net loss to $4.2 million and a 52.1% decrease in adjusted net income to $2.1 million, indicating pressure on operating expenses due to industry-wide fuel costs and increased distribution, selling, and administrative expenses
OUR ANALYSIS → VIEW 8-K →The company reported a net income of $2.36 million, a significant increase from $0.57 million in the previous year, with revenue growth of 10.8% to $3.12 billion, and the operating cash flow was minimal at $15,827 due to increased inventory and accounts receivable.
OUR ANALYSIS → VIEW 8-K →Verde Clean Fuels reported a smaller net loss for Q3 2026 compared to the same period in 2025, primarily due to cost savings initiatives, and maintained a strong balance sheet with $52.6 million in cash and no debt. However, there are no quantified surprises in the filing that would significantly impact the stock price.
OUR ANALYSIS → VIEW 8-K →Alta Equipment Group Inc. reported a net loss of $12.2 million and adjusted EBITDA of $44.9 million, with revenue decreasing 0.7% year over year on an organic basis, but the company's CEO expressed optimism about future prospects due to improving industry conditions and growing backlog
OUR ANALYSIS → VIEW 8-K →Senseonics Holdings, Inc. reported a 140% year-over-year revenue growth in Q3, with revenue of $19.6 million, and raised its full-year 2026 revenue guidance to $68 million to $70 million. The company also achieved a gross margin of approximately 62% during Q3 and raised its full-year gross margin guidance to more than 60%.
OUR ANALYSIS → VIEW 8-K →Repay Holdings Corp reported a 97% revenue growth and a raise in expected annualized cost synergy run-rate to $11 million, but also a net loss of $10.4 million and a free cash flow of ($21.1) million, reflecting a $14 million investment in a bank reseller channel partnership.
OUR ANALYSIS → VIEW 8-K →The company announced a $50 million share repurchase program and a record $5 billion in average tokenized assets, but also reported a net loss of $66.3 million, with approximately 90% of the loss being non-cash expenses. The acquisition of River One is expected to expand the company's addressable market and create new revenue opportunities.
OUR ANALYSIS → VIEW 8-K →WEBTOON Entertainment reported a net loss of $7.5 million and adjusted EBITDA of $2.2 million, with revenue declining 4.0% year-over-year, but expects revenue growth of 9.0%-12.0% on a constant currency basis in the fourth quarter, which is a quantified surprise
OUR ANALYSIS → VIEW 8-K →Casella Waste Systems reported Q3 revenue growth of 15.2% and Adjusted EBITDA growth of 11.4%, driven by acquisitions and organic growth, but net loss was $7.0 million due to an impairment charge and higher expenses. The company narrowed its 2026 guidance for Adjusted EBITDA and raised revenue guidance.
OUR ANALYSIS → VIEW 8-K →Quantum Corp reported a 42.9% year-over-year revenue increase to $89.6 million, with non-GAAP adjusted net income of $9.8 million, or $0.25 per share, and non-GAAP adjusted EBITDA of $11.1 million, driven by strong demand across its secondary storage portfolio, including a record backlog of nearly $100 million and significant purchase orders, including a major hyperscale deployment of its Scalar i
OUR ANALYSIS → VIEW 8-K →The company reported a cash position of $1.2 billion, which is expected to fund operations through 2028, and announced progress in its Phase 3 clinical trials for aleniglipron, but no quantified surprises were disclosed.
OUR ANALYSIS → VIEW 8-K →The company reported its Q3 financial and operating results, which may have been already priced in by the market, and the filing does not contain any quantified surprises.
OUR ANALYSIS → VIEW 8-K →GeneDx reported third quarter 2026 revenue of $123.1 million, a 5% year-over-year increase, and expanded adjusted gross margin to 72%, but the results are largely in line with expectations, and the company is reiterating its full year 2026 revenue guidance of $475 to $490 million.
OUR ANALYSIS → VIEW 8-K →The company reported net income of $3.2 million and Cash Available for Distribution of $3.8 million, with total assets of $1.35 billion, but the filing lacks a quantified surprise to drive a significant price move.
OUR ANALYSIS → VIEW 8-K →Myomo reported record revenue of $12.3 million, a 22% year-over-year increase, and narrowed its full-year revenue guidance to $46-47 million, with breakeven Adjusted EBITDA and sequentially lower cash burn. The company's progress on its four success pillars, including a shift to recurring patient sources and increased market access, contributed to the positive results.
OUR ANALYSIS → VIEW 8-K →Maze Therapeutics reported a strong balance sheet with $477 million in cash and provided updates on its clinical trials, including the completion of enrollment in the Phase 2 HORIZON trial of MZE829, but did not disclose any quantified surprises or significant changes to guidance.
OUR ANALYSIS → VIEW 8-K →Octave Specialty Group reported a 35% growth in total revenue to $58 million in its Insurance Distribution Segment and a 28% growth in total revenues to $85.3 million, with Adjusted EBITDA to shareholders of $10.5 million, driven by strong organic growth and progress in its Everspan business, despite a competitive P&C market
OUR ANALYSIS → VIEW 8-K →The Trade Desk announced a $731 million increase to its share repurchase authorization and reported Q3 financial results that were ahead of expectations, but the company still operates below its expected growth level. The share repurchase program may be viewed positively, but the lack of significant surprises in the earnings report limits the potential impact.
OUR ANALYSIS → VIEW 8-K →The company announced a restatement of its previously issued financial statements due to errors in revenue calculation and accounting for software subscriptions, which led to a material weakness in internal controls over financial reporting. This restatement and material weakness are likely to negatively impact investor confidence.
OUR ANALYSIS → VIEW 8-K →Zentalis Pharmaceuticals reported its Q3 2026 financial results and business updates, including strengthened survival data for azenosertib and a cash runway into 1H 2028, but no quantified surprise or significant news that would move the stock beyond 1.5% in a week
OUR ANALYSIS → VIEW 8-K →Ameresco's Q3 revenue and operating income exceeded prior year, but net income fell due to higher interest expense and a smaller tax benefit; the filing lacks a specific quantified surprise to predict a significant stock move.
OUR ANALYSIS → VIEW 8-K →The company announced a proposed merger with an investor group led by Sequence AI Holdings, Inc. and DFO Management, LLC, where stockholders will receive $32.50 per share in cash, and also reported a 31% year-over-year increase in total revenue to $480.3 million, with adjusted EBITDA growth of 47% to $106.9 million.
OUR ANALYSIS → VIEW 8-K →The company reported a 205% year-over-year revenue growth and a strong balance sheet with $2.5 billion in total assets, but also a $12.3 million Adjusted EBITDA loss, and is advancing its proposed merger with TAE Technologies.
OUR ANALYSIS → VIEW 8-K →Kemper Corporation reported a significant improvement in net income and adjusted consolidated net operating income for the third quarter of 2026, driven by improved Personal Auto performance and profitability, with net income of $52.4 million or $0.88 per diluted share, compared to a net loss of $21.0 million or $(0.34) per share in the third quarter of 2025.
OUR ANALYSIS → VIEW 8-K →NHI reported a significant gain from the sale of the National Healthcare Corporation leased portfolio, but normalized FFO per diluted share decreased 15.2% year-over-year, indicating potential pressure on sustainable growth. The company's ample capital and continued investments in private-pay senior housing may support long-term value creation, but the near-term impact is uncertain.
OUR ANALYSIS → VIEW 8-K →Csquare, Inc. reported strong Q3 results with 25.6% year-over-year revenue growth and record bookings of $66.1 million, driven by sustained demand for its enterprise infrastructure platform, but also posted a net loss of $88.1 million due to IPO-related costs and higher interest expense. The company's adjusted EBITDA increased 44.3% to $132.1 million with an expanded margin of 47.8%.
OUR ANALYSIS → VIEW 8-K →Ultralife Corporation reported strong third quarter results with revenue and gross profit increases, and also announced a pending acquisition by EnerSys in an all-cash transaction valued at approximately $320 million, including the assumption of net debt.
OUR ANALYSIS → VIEW 8-K →United-Guardian reported a significant earnings beat with third quarter net sales increasing 54% and net income increasing 247% year-over-year, driven by strong sales growth in pharmaceuticals, personal care, and medical lubricants.
OUR ANALYSIS → VIEW 8-K →The company reported flat revenue of $32.2 million for the third quarter, with a net loss of $13.4 million driven by platform costs and increased intangible asset amortization expenses. Adjusted EBITDA decreased by $5.5 million to $10.1 million due to platform costs and inflationary pressures.
OUR ANALYSIS → VIEW 8-K →OneMedNet reports $18.76 million in year-to-date contracted bookings, a significant increase from full-year 2025 bookings, with roughly half of 2026 contracts from new customers, indicating strong execution of their strategy.
OUR ANALYSIS → VIEW 8-K →Mereo BioPharma reported a cash position of $26.1 million, expected to fund operations into late-2027, and announced progress on its setrusumab and alvelestat programs, including ongoing regulatory interactions and potential milestone payments, but no quantified surprises were disclosed.
OUR ANALYSIS → VIEW 8-K →The company's net loss of $284.6 million and significant cash used in operating activities of $322.3 million raise concerns about its financial health, and the liabilities subject to compromise of $2,559.2 million add to the uncertainty.
OUR ANALYSIS → VIEW 8-K →OPAL Fuels reported Q3 Adjusted EBITDA of $26.7 million, in line with expectations, and announced 32% Adjusted EBITDA growth compared to the same period last year, driven by progress in RNG production and growth in Fuel Station Services. The company's guidance for full-year Adjusted EBITDA is expected to be within the lower end of the range.
OUR ANALYSIS → VIEW 8-K →Quanterix reported a 6.3% sequential revenue increase to $35.0 million and an improved net loss, with the company citing progress in its commercial effectiveness initiatives and strategic investments in diagnostics, particularly in Alzheimer's disease testing.
OUR ANALYSIS → VIEW 8-K →Uniti Group Inc. reported a net loss of $244.5 million for the third quarter, but raised its full-year revenue guidance, driven by record bookings and growth in fiber revenue, with consolidated revenue and adjusted EBITDA of $848.1 million and $289.3 million, respectively.
OUR ANALYSIS → VIEW 8-K →The company's third-quarter net product revenue was $21 million, with cash and cash equivalents of $189.2 million, and a strategic financial restructuring has extended the expected cash runway into 2029, but the filing also includes a private investment in public equity (PIPE) financing that could lead to dilution.
OUR ANALYSIS → VIEW 8-K →Delcath Systems, Inc. reported a significant increase in revenue and net income for the third quarter of 2026, with total revenue of $35.1 million and net income of $7.0 million, and also raised its 2026 revenue guidance to a range of $115 million to $117 million. The company's strong financial performance and increased guidance are likely to have a positive impact on the stock price.
OUR ANALYSIS → VIEW 8-K →RB Global reported a strong third quarter with 20% year-over-year growth in gross transaction value and 17% growth in revenue, exceeding expectations and prompting an update to its full-year outlook. The company's share repurchase program has also been active, with $500 million remaining under the Normal Course Issuer Bid.
OUR ANALYSIS → VIEW 8-K →The company reported a 27.0% increase in total consolidated net sales and a 114.2% increase in Modern Oral gross sales, but net income decreased 81.4% due to increased sales and marketing investments. The company reaffirmed its FY 2026 guidance, which may not be enough to offset the significant decline in net income.
OUR ANALYSIS → VIEW 8-K →WhiteHorse Finance's Q3 results show a modest increase in core net investment income and a decline in non-accruals, but the company's net investment income per share decreased by 4.7% due to higher expenses. The incentive fee waiver by WhiteHorse Advisers may provide some relief, but its impact is limited to the next fiscal quarter.
OUR ANALYSIS → VIEW 8-K →Compass Therapeutics reported $163 million in cash and marketable securities, which is expected to fund operations into 2028, and provided updates on its pipeline assets, including preparations for a BLA submission for tovecimig and ongoing cohort expansions for CTX-8371 and CTX-10726, but there are no quantified surprises in the filing.
OUR ANALYSIS → VIEW 8-K →Motorcar Parts of America reported fiscal Q2 results with net sales of $169.2 million, down from $221.5 million in the prior-year quarter, and announced approximately $60 million in new annualized customer business awards, with shipments beginning and further launches expected this fiscal year. However, the company's guidance reflects increased sales for the second half of the current fiscal year
OUR ANALYSIS → VIEW 8-K →Bicara Therapeutics reported substantial enrollment in its FORTIFI-HN01 pivotal trial and provided a business update, with cash and equivalents expected to fund operations into the first half of 2029, but no quantified surprises were disclosed in the filing.
OUR ANALYSIS → VIEW 8-K →RadNet's third-quarter revenue and adjusted EBITDA exceeded expectations, with a 22.1% and 23.8% increase, respectively, driven by growth in advanced imaging and digital health segments, and the company has revised its 2026 guidance upwards. The strong financial performance and healthy balance sheet position the company for further growth and strategic acquisitions.
OUR ANALYSIS → VIEW 8-K →ImmunityBio reported Q3 2026 net product revenue of $48.7 million, up 53% year-over-year, and a 92% increase in year-to-date revenue to $143.6 million, driven by continued adoption of ANKTIVA among U.S. urologists and strong market access, with the company also announcing expanded FDA approval and global expansion of ANKTIVA in non-muscle invasive bladder cancer (NMIBC).
OUR ANALYSIS → VIEW 8-K →The company reported its fiscal quarter results and provided a business update, but the filing does not contain any quantified surprises, such as earnings or guidance beats, that would likely move the stock price beyond 1.5% in a week.
OUR ANALYSIS → VIEW 8-K →AMG reported a 56% year-over-year increase in Economic EPS and a record $974 billion in AUM, with $21 billion in net client cash flows during Q3, including $31 billion in alternative net inflows. The company also repurchased $400 million in common stock, bringing year-to-date repurchases to $775 million.
OUR ANALYSIS → VIEW 8-K →Foghorn Therapeutics reported a strong balance sheet with $156 million in cash and a cash runway into the second half of 2029, and provided updates on its pipeline programs, including a novel oral small molecule in inflammatory bowel disease and a selective EP300 degrader for multiple myeloma, but no quantified surprises were disclosed.
OUR ANALYSIS → VIEW 8-K →Select Water Solutions reported a strong third quarter with 28% year-over-year revenue growth and a 57% increase in Adjusted EBITDA, driven by record Water Infrastructure revenue and the completion of a recapitalization and sale of a majority interest in Peak Rentals, as well as the subsequent acquisition of Pilot Water Solutions, which is expected to drive further growth in the Water Infrastructu
OUR ANALYSIS → VIEW 8-K →Editas Medicine announced progress in advancing EDIT-401, a potentially best-in-class in vivo gene editing medicine for hyperlipidemia, with regulatory approval to initiate the Strive study in Australia and new preclinical durability data showing ≥90 percent LDL-C reduction maintained over 10 months, as well as a milestone payment from Bristol Myers Squibb for a second IND/CTA acceptance
OUR ANALYSIS → VIEW 8-K →The company has $141.9 million in cash and cash equivalents, and its current cash is expected to support operating plans into mid-2027, but there are no quantified surprises in the filing.
OUR ANALYSIS → VIEW 8-K →Turn Therapeutics reported encouraging results from its Stage 1/Phase 2a trial of GX-03 in atopic dermatitis, with 59.3% of patients achieving clear or almost clear skin after four weeks, and is accelerating its Phase 2a trial of GX-03 in hidradenitis suppurativa, now expected to begin in the first quarter of 2027. The company also expects to report topline results from its Phase 2b trial in the f
OUR ANALYSIS → VIEW 8-K →Via Transportation, Inc. reported a milestone quarter with 31% revenue growth, record pipeline, and Adjusted Net Loss per Share rounding to breakeven, driven by strong execution and progress towards profitability.
OUR ANALYSIS → VIEW 8-K →KKR reports record Fee Related Earnings, Total Operating Earnings, and Adjusted Net Income per share for the third quarter, with expected returns to clients exceeding $40 billion in 2026, a 50% increase over the previous annual record.
OUR ANALYSIS → VIEW 8-K →Target Hospitality Corp. reported a 30% year-over-year revenue increase to $129.1 million and a 59% year-over-year increase in adjusted EBITDA to $34.2 million, driven by significant growth in the Workforce Hospitality Solutions segment, with a total contract value exceeding $1.7 billion and over 10,000 beds secured since January 2026.
OUR ANALYSIS → VIEW 8-K →Berkshire Hathaway's Q3 operating earnings were $12.705 billion, down from $13.485 billion in Q3 2025, and net earnings attributable to Berkshire shareholders were $22.112 billion, down from $30.796 billion in Q3 2025. The earnings release does not contain any significant surprises or quantified beats, so the impact is likely to be neutral.
OUR ANALYSIS → VIEW 8-K →The company announced its Q3 financial results and declared a dividend of $0.42 per share, but there are no quantified surprises, and the appointment of a new independent director is a routine matter.
OUR ANALYSIS → VIEW 8-K →Elmet Group Co. reported a 55.6% revenue increase to $79.6 million and a 129.4% adjusted EBITDA increase to $17.0 million, driven by demand in Aerospace, Defense, and Government markets, with a record backlog of $347.4 million, and a landmark $450 million investment to secure tungsten supply chain.
OUR ANALYSIS → VIEW 8-K →Gladstone Investment Corporation reported a net increase in net assets resulting from operations of $17.1 million, or $0.43 per share, and a net asset value per common share of $16.43, but this was largely due to net unrealized appreciation of $12.2 million, and net investment income per share declined 70% year-over-year to $0.12, which may not be sustainable and could impact future distributions
OUR ANALYSIS → VIEW 8-K →The company reported record net daily production and Adjusted EBITDAX, with a 100% increase in net daily production and a 104% increase in natural gas net production compared to the third quarter of 2025. The company also narrowed its 2026 guidance, indicating a positive outlook for the remainder of the year.
OUR ANALYSIS → VIEW 8-K →EVI Industries reported record first fiscal quarter results with revenue increasing 4.3% to $112.9 million, gross profit increasing 12% to $38.0 million, and net income increasing 108% to $3.8 million, driven by growth in commercial laundry and the acquisition of Sudsies, Inc.
OUR ANALYSIS → VIEW 8-K →OraSure Technologies reported a 14% year-over-year revenue growth in Q3, driven by a 16% increase in diagnostics revenues and a 21% increase in sample management solutions revenues, with a GAAP gross margin expansion of 170 basis points to 45.2%
OUR ANALYSIS → VIEW 8-K →Onto Innovation reported record quarterly revenue of $410 million, exceeding the high end of previously announced non-GAAP guidance ranges, with revenue growth of 88% year-over-year and 19% sequentially, driven by strong adoption of its products in the markets it serves.
OUR ANALYSIS → VIEW 8-K →The company reported financial results and provided corporate updates, highlighting advancements in the neflamapimod clinical development program for dementia with Lewy bodies and other neurodegenerative disorders, but did not disclose any quantified surprises or significant financial updates that would impact the stock price beyond routine expectations.
OUR ANALYSIS → VIEW 8-K →Air Industries Group reported significantly improved financial results for the three and nine months ended September 30, 2026, with net sales increasing by 41.1% and 8.7% respectively, and gross profit improving by 61.4% and 38.3% respectively. However, operating expenses included non-cash and one-time extraordinary costs related to a pending merger, which impacted net income and operating income.
OUR ANALYSIS → VIEW 8-K →GCM Grosvenor reports strong Q3 2026 results with GAAP Net Income up 17% and Adjusted Net Income up 20% year-over-year, also announces a $0.12 per share dividend payable on December 15, 2026
OUR ANALYSIS → VIEW 8-K →Ferguson Enterprises Inc. reported strong Q3 results with 9.5% sales growth and raised full-year guidance, driven by non-residential sales up 15% and residential growth of 6%, with a strong balance sheet and net debt to adjusted EBITDA of 1.7x.
OUR ANALYSIS → VIEW 8-K →Lafayette Square USA, Inc. reported a 36.2% increase in total assets and a 36.8% increase in net assets year-over-year, with a weighted average yield at amortized cost of 10.6% and a net interest margin of 4.7%.
OUR ANALYSIS → VIEW 8-K →Network-1 Technologies reported a net loss of $2.33 million, or $0.10 per share, for the third quarter, with increased operating expenses due to higher litigation-related professional fees and net unrealized losses on marketable securities, and the company continues to pursue four pending patent litigations.
OUR ANALYSIS → VIEW 8-K →Immunovant's IMVT-1402 met the primary endpoint of ACR20 response at Week 28 in a potentially registrational trial for difficult-to-treat rheumatoid arthritis, with 92.5% response rate vs 75.6% for placebo, and the company plans FDA discussions for later this year to determine the path forward
OUR ANALYSIS → VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →The material filings, RNS and EU notices in one email every market day, read and scored by AI.
Subscribe free →Nov 10 (58) · Nov 6 (83) · Nov 5 (348) · Nov 4 (277) · Nov 3 (185) · Nov 2 (126) · Oct 30 (64) · Oct 29 (248) · Oct 28 (199) · Oct 27 (164) · Oct 26 (70) · Oct 23 (37) · Oct 22 (131) · Oct 21 (108) · Oct 20 (68) · Oct 19 (30) · Oct 16 (14) · Oct 15 (37) · Oct 14 (23) · Oct 13 (28)